Skip to main content

CORRECTION article

Front. Oncol., 07 November 2023
Sec. Thoracic Oncology
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1309950

Corrigendum: Development and validation of a m6A -regulated prognostic signature in lung adenocarcinoma

This article is a correction to:

  1. Development and validation of a m6A -regulated prognostic signature in lung adenocarcinoma

    1. Read original article
Yaxin ChenYaxin Chen1Lei XiaLei Xia2Yuxuan PengYuxuan Peng1Gang WangGang Wang3Liyun BiLiyun Bi3Xue XiaoXue Xiao1Cui LiCui Li1Weimin Li,,,*Weimin Li1,3,4,5*
  • 1Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
  • 2Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, China
  • 3Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China
  • 4Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China
  • 5The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital, Chengdu, China

A Corrigendum on
Development and validation of a m6A-regulated prognostic signature in lung adenocarcinoma

by Chen Y, Xia L, Peng Y, Wang G, Bi L, Xiao X, Li C and Li W (2022) Front. Oncol. 12:947808. doi: 10.3389/fonc.2022.947808

In the published article, there was an error in affiliation 1. Instead of Frontiers Science Center for Disease-related Molecular Network, Sichuan University, Chengdu, China, it should be Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Additionally, in the published article, there was an error in the Data Availability statement. Instead of The data presented in this study have been deposited in the Genome Sequence Archive (GSA) in BIG Data Center, Beijing Institute of Genomics (BIG) under accession number HRA003044 (https://ngdc.cncb.ac.cn/gsa-human/s/epL1lQWd).

The correct Data Availability Statement appears below:

The data presented in this study have been deposited in the Genome Sequence Archive (GSA) in BIG Data Center, Beijing Institute of Genomics (BIG) under accession number HRA003044 (https://ngdc.cncb.ac.cn/gsa-human/browse/HRA003044).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Furthermore, in the published article, there was an error in the Funding statement. The funding statement for the Fundamental Research Funds for the Central Universities was displayed as “20826041F4147. The correct statement is “Fundamental Research Funds for the Central Universities (No. 2022SCU12047 to Y. Chen)’’. The correct Funding statement appears below.

“This study was supported by National Natural Science Foundation of China (Nos. 81871890, 91859203 to WL), Post-Doctor Research Project, West China Hospital, Sichuan University (2021HXBH051), Sichuan Science and Technology Support Project (No. 2022NSFSC1516 to YC) and the Fundamental Research Funds for the Central Universities (No. 2022SCU12047 to Y. Chen)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: m6A, prognosis, signature, lung adenocarcinoma, epitranscriptomic

Citation: Chen Y, Xia L, Peng Y, Wang G, Bi L, Xiao X, Li C and Li W (2023) Corrigendum: Development and validation of a m6A -regulated prognostic signature in lung adenocarcinoma. Front. Oncol. 13:1309950. doi: 10.3389/fonc.2023.1309950

Received: 09 October 2023; Accepted: 18 October 2023;
Published: 07 November 2023.

Edited and Reviewed by:

Deguan Lv, University of Pittsburgh Medical Center, United States

Copyright © 2023 Chen, Xia, Peng, Wang, Bi, Xiao, Li and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Weimin Li, weimi003@scu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.